Identification and profiling of novel α 1A-adrenoceptor-CXC chemokine receptor 2 heteromer

Journal of Biological Chemistry

Volumn 287, Issue 16, 2012, Pages 12952-12965

  Mustafa, Sanam ^a   See, Heng B ^a   Seeber, Ruth M ^a   Armstrong, Stephen P ^a   White, Carl W ^b   Ventura, Sabatino ^b   Ayoub, Mohammed Akli ^a   Pfleger, Kevin D G ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Dimerix Bioscience Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

293 CELLS; ARRESTINS; BIOLOGICAL FUNCTIONS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL-BASED; CHEMOKINE RECEPTORS; CO-EXPRESSION; COLOCALIZATION; G-PROTEIN COUPLED RECEPTORS; HUMAN EMBRYONIC KIDNEYS; IDENTIFICATION TECHNOLOGY; INOSITOL PHOSPHATE; LIVE CELL; SMOOTH MUSCLE LAYER;

CONFOCAL MICROSCOPY; SUGARS; UROLOGY;

EMPLOYMENT;

ALPHA 1A ADRENERGIC RECEPTOR; BETA ARRESTIN; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CXCR2; G PROTEIN COUPLED RECEPTOR; INOSITOL PHOSPHATE; LABETALOL; NORADRENALIN; SB 265610; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL STRAIN HEK293; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TARGETING; HETEROMERIZATION; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; SMOOTH MUSCLE; STROMA;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-AGONISTS; ALLOSTERIC REGULATION; ANIMALS; ARRESTINS; CHEMOKINES; CHO CELLS; CRICETINAE; HEK293 CELLS; HUMANS; INOSITOL PHOSPHATES; LABETALOL; MALE; MICE; MICE, INBRED C57BL; NOREPINEPHRINE; PRAZOSIN; PROSTATE; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, INTERLEUKIN-8B;

EID: 84859768529     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.322834     Document Type: Article

References (67)

1. Kenakin, T. P. (2009) Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 8, 617-626
2. Ferré, S., Baler, R., Bouvier, M., Caron, M. G., Devi, L. A., Durroux, T., Fuxe, K., George, S. R., Javitch, J. A., Lohse, M. J., Mackie, K., Milligan, G., Pfleger, K. D., Pin, J. P., Volkow, N. D., Waldhoer, M., Woods, A. S., and Franco, R. (2009) Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 5, 131-134
3. Whorton, M. R., Bokoch, M. P., Rasmussen, S. G., Huang, B., Zare, R. N., Kobilka, B., and Sunahara, R. K. (2007) A monomeric G protein-coupled receptor isolated in a high density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. U.S.A. 104, 7682-7687 (Pubitemid 47185966)
4. Ernst, O. P., Gramse, V., Kolbe, M., Hofmann, K. P., and Heck, M. (2007) Monomeric G protein-coupled receptor rhodopsin in solution activates its G protein transducin at the diffusion limit. Proc. Natl. Acad. Sci. U.S.A. 104, 10859-10864 (Pubitemid 47175191)
5. Whorton, M. R., Jastrzebska, B., Park, P. S., Fotiadis, D., Engel, A., Palczewski, K., and Sunahara, R. K. (2008) Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J. Biol. Chem. 283, 4387-4394
6. i2. J. Biol. Chem. 284, 26732-26741
7. Eckert, R. E., Schreier, U., Drescher, P., Madsen, P. O., Derouet, H., Becht, E., Steffens, J., and Ziegler, M. (1995) Regulation of prostatic smooth muscle contractility by intracellular second messengers. Implications for the conservative treatment of benign prostatic hyperplasia. Urol. Int. 54, 6-21
8. Muramatsu, I., Oshita, M., Ohmura, T., Kigoshi, S., Akino, H., Gobara, M., and Okada, K. (1994) Pharmacological characterization of α1-adrenoceptor subtypes in the human prostate. Functional and binding studies. Br. J. Urol. 74, 572-578 (Pubitemid 24348622)
9. Ford, A. P., Arredondo, N. F., Blue, D. R., Jr., Bonhaus, D. W., Jasper, J., Kava, M. S., Lesnick, J., Pfister, J. R., Shieh, I. A., Vimont, R. L., Williams, T. J., McNeal, J. E., Stamey, T. A., and Clarke, D. E. (1996) RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-α,α-dimethyl-1H- indole-3-ethanamine hydrochloride), a selective α 1A-adrenoceptor antagonist, displays low affinity for functional α 1-adrenoceptors in human prostate. implications for adrenoceptor classification. Mol. Pharmacol. 49, 209-215
10. Gray, K., Short, J., and Ventura, S. (2008) The α1A-adrenoceptor gene is required for the α1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br. J. Pharmacol. 155, 103-109
11. Shibata, K., Hirasawa, A., Moriyama, N., Kawabe, K., Ogawa, S., and Tsujimoto, G. (1996) α1a-adrenoceptor polymorphism. Pharmacological characterization and association with benign prostatic hypertrophy. Br. J. Pharmacol. 118, 1403-1408 (Pubitemid 26248791)
12. Suzuki, F., Taniguchi, T., Takauji, R., Murata, S., and Muramatsu, I. (2000) Splice isoforms of α(1a)-adrenoceptor in rabbit. Br. J. Pharmacol. 129, 1569-1576
13. Ramsay, D., Carr, I. C., Pediani, J., Lopez-Gimenez, J. F., Thurlow, R., Fidock, M., and Milligan, G. (2004) High affinity interactions between human α1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the α1L-adrenoceptor. Mol. Pharmacol. 66, 228-239 (Pubitemid 38989479)
14. Muramatsu, I., Tanaka, T., Suzuki, F., Li, Z., Hiraizumi-Hiraoka, Y., Anisuzzaman, A. S., Yamamoto, H., Horinouchi, T., and Morishima, S. (2005) Quantifying receptor properties. The tissue segment binding method; a powerful tool for the pharmacome analysis of native receptors. J. Pharmacol. Sci. 98, 331-339 (Pubitemid 41297006)
15. Nishimune, A., Suzuki, F., Yoshiki, H., Morishima, S., and Muramatsu, I. (2010)α1-Adrenoceptor pharmacome. α1L-adrenoceptor and α1A-adrenoceptor in the lower urinary tract. Int. J. Urol. 17, 31-37
16. Nishimune, A., Suzuki, F., Yoshiki, H., Morishima, S., and Muramatsu, I. (2010) Identification of cysteine-rich epidermal growth factor-like domain 1α (CRELD1α) as a novel α1A-adrenoceptor-down-regulating protein and establishment of an α1L-adrenoceptor-expressing cell line. J. Pharmacol. Sci. 113, 169-181
17. Uberti, M. A., Hall, R. A., and Minneman, K. P. (2003) Subtype-specific dimerization of α 1-adrenoceptors. Effects on receptor expression and pharmacological properties. Mol. Pharmacol. 64, 1379-1390 (Pubitemid 37532228)
18. LaRocca, T. J., Schwarzkopf, M., Altman, P., Zhang, S., Gupta, A., Gomes, I., Alvin, Z., Champion, H. C., Haddad, G., Hajjar, R. J., Devi, L. A., Schecter, A. D., and Tarzami, S. T. (2010) β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J. Cardiovasc. Pharmacol. 56, 548-559
19. Cotecchia, S. (2010) The α1-adrenergic receptors. Diversity of signaling networks and regulation. J. Recept. Signal. Transduct. Res. 30, 410-419
20. Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., Takatsu, Y., Melamed, J., d'Adda di Fagagna, F., Bernard, D., Hernando, E., and Gil, J. (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018
21. Trettel, F., Di Bartolomeo, S., Lauro, C., Catalano, M., Ciotti, M. T., and Limatola, C. (2003) Ligand-independent CXCR2 dimerization. J. Biol. Chem. 278, 40980-40988 (Pubitemid 37280920)
22. Wilson, S., Wilkinson, G., and Milligan, G. (2005) The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J. Biol. Chem. 280, 28663-28674 (Pubitemid 41105767)
23. Parenty, G., Appelbe, S., and Milligan, G. (2008) CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem. J. 412, 245-256 (Pubitemid 351758230)
24. Mustafa, S., Ayoub, M. A., and Pfleger, K. D. (2010) Uncovering GPCR heteromer-biased ligands. Drug Discov. Today: Technol. 7, e77-e85
25. Morishima, S., Suzuki, F., Nishimune, A., Yoshiki, H., Akino, H., Yokoyama, O., and Muramatsu, I. (2010) Visualization and tissue distribution of α1L-adrenoceptor in human prostate by the fluorescently labeled ligand Alexa-488-silodosin. J. Urol. 183, 812-819
26. Ayoub, M. A., and Pfleger, K. D. (2010) Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. Curr. Opin. Pharmacol. 10, 44-52
27. See, H. B., Seeber, R. M., Kocan, M., Eidne, K. A., and Pfleger, K. D. (2011) Application ofGprotein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers. Assay Drug Dev. Technol. 9, 21-30
28. Mustafa, S., and Pfleger, K. D. (2011) G protein-coupled receptor heteromer identification technology. Identification and profiling of GPCR heteromers. J. Lab. Autom. 16, 285-291
29. Porrello, E. R., Pfleger, K. D., Seeber, R. M., Qian, H., Oro, C., Abogadie, F., Delbridge, L. M., and Thomas, W. G. (2011) Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles. Cell. Signal. 23, 1767-1776
30. Stanasila, L., Abuin, L., Dey, J., and Cotecchia, S. (2008) Different internalization properties of the α1a- and α1b-adrenergic receptor subtypes. The potential role of receptor interaction with β-arrestins and AP50. Mol. Pharmacol. 74, 562-573
31. Hennenberg, M., Schlenker, B., Roosen, A., Strittmatter, F., Walther, S., Stief, C., and Gratzke, C. (2011) β-Arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors. World J. Urol. 29, 157-163
32. Loening, A. M., Fenn, T. D., Wu, A. M., and Gambhir, S. S. (2006) Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng. Des. Sel. 19, 391-400 (Pubitemid 44306057)
33. Kocan, M., See, H. B., Seeber, R. M., Eidne, K. A., and Pfleger, K. D. (2008) Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells. J. Biomol. Screen. 13, 888-898
34. Kocan, M., See, H. B., Sampaio, N. G., Eidne, K. A., Feldman, B. J., and Pfleger, K. D. (2009) Agonist-independent interactions between β-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. Mol. Endocrinol. 23, 559-571
35. Pfleger, K. D., Dromey, J. R., Dalrymple, M. B., Lim, E. M., Thomas, W. G., and Eidne, K. A. (2006) Extended bioluminescence resonance energy transfer (eBRET) for monitoring prolonged protein-protein interactions in live cells. Cell. Signal. 18, 1664-1670
36. Pfleger, K. D., Seeber, R. M., and Eidne, K. A. (2006) Bioluminescence resonance energy transfer (BRET) for the real-time detection of proteinprotein interactions. Nat. Protoc. 1, 337-345
37. Trinquet, E., Fink, M., Bazin, H., Grillet, F., Maurin, F., Bourrier, E., Ansanay, H., Leroy, C., Michaud, A., Durroux, T., Maurel, D., Malhaire, F., Goudet, C., Pin, J. P., Naval, M., Hernout, O., Chrétien, F., Chapleur, Y., and Mathis, G. (2006) D-myo-Inositol 1-phosphate as a surrogate of Dmyo- inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal. Biochem. 358, 126-135 (Pubitemid 44511899)
38. Wang, Y., Luo, W., and Reiser, G. (2007) Activation of protease-activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth-regulated oncogene/cytokine-induced neutrophil chemoattractant family. Eur. J. Neurosci. 26, 3159-3168 (Pubitemid 350135183)
39. Sugimoto, N., Rui, T., Yang, M., Bharwani, S., Handa, O., Yoshida, N., Yoshikawa, T., and Kvietys, P. R. (2008) Points of control exerted along the macrophage-endothelial cell-polymorphonuclear neutrophil axis by PECAM- 1 in the innate immune response of acute colonic inflammation. J. Immunol. 181, 2145-2154
40. Martínez Muñoz, L., Lucas, P., Navarro, G., Checa, A. I., Franco, R., Martínez- A, C., Rodríguez-Frade, J. M., and Mellado, M. (2009) Dynamic regulation of CXCR1 and CXCR2 homo- and heterodimers. J. Immunol. 183, 7337-7346
41. Moldobaeva, A., and Wagner, E. M. (2005) Difference in proangiogenic potential of systemic and pulmonary endothelium. role of CXCR2. Am. J. Physiol. Lung Cell Mol. Physiol. 288, L1117-L1123 (Pubitemid 40695437)
42. Kojima, Y., Sasaki, S., Hayashi, Y., Tsujimoto, G., and Kohri, K. (2009) Subtypes of α1-adrenoceptors in BPH. Future prospects for personalized medicine. Nat. Clin. Pract. Urol. 6, 44-53
43. Hieble, J. P., and Ruffolo, R. R., Jr. (1996) The use of α-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy. An overview. Pharmacol. Res. 33, 145-160 (Pubitemid 26300700)
44. Bradley, M. E., Bond, M. E., Manini, J., Brown, Z., and Charlton, S. J. (2009) SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br. J. Pharmacol. 158, 328-338
45. Salchow, K., Bond, M. E., Evans, S. C., Press, N. J., Charlton, S. J., Hunt, P. A., and Bradley, M. E. (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br. J. Pharmacol. 159, 1429-1439
46. Levoye, A., Dam, J., Ayoub, M. A., Guillaume, J. L., Couturier, C., Delagrange, P., and Jockers, R. (2006) The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 25, 3012-3023 (Pubitemid 44106754)
47. Galandrin, S., and Bouvier, M. (2006) Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70, 1575-1584
48. Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., and Lefkowitz, R. J. (2007) A unique mechanism of β-blocker action. Carvedilol stimulates β-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 104, 16657-16662 (Pubitemid 350211072)
49. Rajagopal, S., Rajagopal, K., and Lefkowitz, R. J. (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386
50. Jensen, B. C., Swigart, P. M., and Simpson, P. C. (2009) Ten commercial antibodies for α-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch. Pharmacol. 379, 409-412
51. Bulenger, S., Marullo, S., and Bouvier, M. (2005) Emerging role of homoand heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26, 131-137 (Pubitemid 40313592)
52. Milligan, G. (2008) A day in the life of a G protein-coupled receptor. The contribution to function ofGprotein-coupled receptor dimerization. Br. J. Pharmacol. 153, S216-S229
53. Lohse, M. J. (2010) Dimerization in GPCR mobility and signaling. Curr. Opin. Pharmacol. 10, 53-58
54. Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E., Lazareno, S., Molloy, J. E., and Birdsall, N. J. (2010) Formation and dissociation ofM1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. U.S.A. 107, 2693-2698
55. Schelshorn, D., Joly, F., Mutel, S., Hampe, C., Breton, B., Mutel, V., and Lütjens, R. (2012) Lateral allosterism in the glucagon receptor family. Glucagon- like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol. Pharmacol. 81, 309-318
56. Rovira, X., Pin, J. P., and Giraldo, J. (2010) The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signaling pathways. Trends Pharmacol. Sci. 31, 15-21
57. Maurice, P., Kamal, M., and Jockers, R. (2011) Asymmetry of GPCR oligomers supports their functional relevance. Trends Pharmacol. Sci. 32, 514-520
58. Pfleger, K. D., and Eidne, K. A. (2006) Illuminating insights into proteinprotein interactions using bioluminescence resonance energy transfer (BRET). Nat. Methods 3, 165-174
59. Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., and Caron, M. G. (1999) Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem. 274, 32248-32257
60. Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., and Caron, M. G. (2001) Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis. J. Biol. Chem. 276, 19452-19460
61. Vázquez-Prado, J., Medina, L. C., Romero-Avila, M. T., González-Espinosa, C., and García-Sáinz, J. A. (2000) Norepinephrine- and phorbol ester- induced phosphorylation of α(1a)-adrenergic receptors. Functional aspects. J. Biol. Chem. 275, 6553-6559
62. Tobin, A. B., Butcher, A. J., and Kong, K. C. (2008) Location, location, location . . . site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol. Sci. 29, 413-420
63. Butcher, A. J., Prihandoko, R., Kong, K. C., McWilliams, P., Edwards, J. M., Bottrill, A., Mistry, S., and Tobin, A. B. (2011) Differential G-proteincoupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol. Chem. 286, 11506-11518
64. Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., Strachan, R. T., Huang, T. Y., Bressler, E. A., Hara, M. R., Shenoy, S. K., Gygi, S. P., and Lefkowitz, R. J. (2011) Distinct phosphorylation sites on the β2-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci. Signal. 4, ra51
65. Liggett, S. B. (2011) Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci. Signal. 4, pe36
66. Thorsteinsson, A., Johannesdottir, A., Eiríksson, H., and Helgason, H. (2008) Severe labetalol overdose in an 8-month-old infant. Paediatr. Anaesth. 18, 435-438 (Pubitemid 351490490)
67. Dalrymple, M. B., Jaeger, W. C., Eidne, K. A., and Pfleger, K. D. (2011) Temporal profiling of orexin receptor-arrestin-ubiquitin complexes reveals differences between receptor subtypes. J. Biol. Chem. 286, 16726-16733